| Literature DB >> 35164360 |
Fahima Bekka-Hadji1,2, Isabelle Bombarda3, Ferhat Djoudi2, Sofiane Bakour4, Abdelaziz Touati2.
Abstract
The essential oils were obtained by hydrodistillation from aerial parts of Mentha pulegium L. (M. pulegium L.) and Artemisia herba alba (A. herba alba) Asso. and analyzed by gas chromatography-flame ionization detector chromatograpy (GC-FID) and gaz chromatography-mass spectrometry (GC-MS). The antibacterial activities of the oils were determined by the disk diffusion method and a microdilution broth assay against six bacteria stains. The combinations of these essential oils with antibiotics were evaluated against two multi-drug-resistant bacteria strains: imipenem-resistant Acinetobacter baumannii (IRAB S3310) and methicillin-resistant Staphylococcus aureus (MRSA S19). The chemical analysis of M. pulegium essential oil revealed the presence of pulegone (74.8%) and neoisomenthol (10.0%). A. herba alba essential oil was characterized by camphor (32.0%), α-thujone (13.7%), 1,8-cineole (9.8%), β-thujone (5.0%), bornéol (3.8%), camphene (3.6%), and p-cymene (2.1%). All strains tested except Pseudomonas aeruginosa were susceptible to these oils. The combinations of essential oils with antibiotics exerted synergism, antagonism, or indifferent effects. The best effect was observed with A. herba alba essential oil in association with cefoxitin (CX) against MRSA S19. However, for IRAB S3310, the strongest synergistic effect was observed with M. pulegium in association with amikacin (AK). This study demonstrated that M. pulegium and A. herba alba essential oils have antibacterial activities which could be potentiated by antibiotics especially in the case of IRAB S3310.Entities:
Keywords: antibacterial activity; antibiotic; essential oil; multi-drug-resistant bacteria; synergism
Mesh:
Substances:
Year: 2022 PMID: 35164360 PMCID: PMC8839733 DOI: 10.3390/molecules27031095
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Chemical composition of Artemisia herba alba (A. herba alba) essential oil growing wild in Bejaia (Algeria).
| RI a | RI b | Compounds | Relative Composition c |
|---|---|---|---|
| 913 | 924 | α-thujene | 0.3 |
| 924 | 932 | α-pinene | 1.6 |
| 945 | 946 | camphene | 3.6 |
| 974 | 969 | sabinene | 0.3 |
| 981 | 974 | β-pinene | 0.2 |
| 990 | 988 | β-myrcene | 0.3 |
| 1009 | 1002 | α-phellandrene | 0.1 |
| 1015 | 1008 | 3-carene | 0.2 |
| 1020 | 1014 | α-terpinene | 0.2 |
| 1027 | 1020 | 2.1 | |
| 1030 | 1024 | limonene | 0.4 |
| 1035 | 1026 | 1,8-cineole | 9.8 |
| 1058 | 1054 | γ-terpinene | 0.7 |
| 1068 | 1065 | 0.4 | |
| 1091 | 1083 | fenchone | 0.6 |
| 1107 | 1101 | α-thujone | 13.7 |
| 1118 | 1112 | β-thujone | 5.0 |
| 1128 | 1124 | chrysanthenone | 1.7 |
| 1143 | 1139 | pinocarvéol | 1.2 |
| 1151 | 1141 | camphor | 32.0 |
| 1169 | 1167 | menthol | 1.0 |
| 1172 | 1165 | borneol | 3.8 |
| 1183 | 1174 | terpinen-4-ol | 0.9 |
| 1191 | 1179 | 0.2 | |
| 1205 | 1195 | myrtenal | 0.5 |
| 1252 | 1239 | carvone | 0.2 |
| 1296 | 1289 | thymol | 0.6 |
| 1306 | 1298 | carvacrol | 1.7 |
| 1331 | 1324 | myrtenyl acetate | 0.4 |
| 1507 | 1500 | bicyclogermacrene | 0.2 |
| 1532 | 1522 | δ-cadinene | 0.1 |
| 1564 | - | eudesma-3,7(11)-diene | 0.1 |
| 1595 | 1582 | caryophyllene oxide | 0.2 |
| 1615 | 1602 | ledol | 0.1 |
a Retention indices relative to homologous n-alkanes C6–C26 obtained on an HP-5 capillary column. b Retention indices from the literature (Adam, 2007). c Experimental relative area percentage obtained by chromatography (GC) on an HP-5 capillary column.
IZDs (mm) and MICs for Mentha pulegium L. (M. pulegium L.) and A. herba alba Asso. essential oils against bacteria strains.
| Plants | Essential Oil | MRSA S19 | IRABS3310 | ||||
|---|---|---|---|---|---|---|---|
| IZD | 18.2 ± 0.4 | 17.8 ± 2.9 | 20.7 ± 1.6 | 17.2 ± 0.7 | 06.6 ± 0.5 | 25.3 ± 3 | |
| MIC | 1.2 | 2.3 | 1.2 | 9.4 | 75 | 1.2 | |
| IZD | 19.7 ± 0.7 | 13.5 ± 0.0 | 13.2 ± 0.9 | 13.2 ± 0.1 | NZ | 15.3 ± 0.6 | |
| MIC | 1.2 | 1.2 | 1.2 | 4.7 | 18.8 | 1.2 | |
| ciprofloxacin (CIP) | IZD | - | - | - | 34 ± 2.8 | 38.5 ± 0.0 | 14 ± 0.0 |
| amikacin (AK) | IZD | - | - | - | 20 ± 0.0 | 26 ± 0.0 | 12 ± 0.5 |
| oxacillin (OX) | IZD | 25.5 ± 0.7 | 19 ± 0.0 | - | - | - | - |
| cefoxitin (CX) | IZD | 25.5 ± 0.7 | 19.5 ± 0.0 | - | - | - | - |
| vancomycin (VAN) | IZD | 18.8 ± 2.5 | 17.5 ± 0.0 | - | - | - | - |
IZD, the inhibition zone diameter (mm) including the disc diameter of 6 mm. The values are given as the mean ± standard deviation; NZ, no inhibition zone; MIC, minimal inhibitory concentration in µL/mL.
IZDs a (mm) of M. pulegium essential oil and antibiotics, alone and in combination, against MRSA S19 and IRABS3310 bacteria.
| Groups | Antibiotics | Inhibition Zone a with the Antibiotics | Inhibition Zone a with the Essential Oil | Sum of the Inhibitions Zone a with the Antibiotics and Essential Oil | Inhibition Zone a with the Antibiotics and the Essential Oil in Association | Effects b | |
|---|---|---|---|---|---|---|---|
| MRSA S19 | penicillin | OX | 13.0 ± 0.0 | 11.8 ± 2.9 | >24.8 | 19.4 ± 1.5 | A |
| cephalosporines | CX | 13.5 ± 0.0 | 11.8 ± 2.9 | >25.3 | 26.8 ± 0.6 | S | |
| glycopeptids | VAN | 11.5 ± 0.0 | 11.8 ± 2.9 | >23.3 | 14.5 ± 0.0 | A | |
| IRAB | penicillin | TIC | NZ | 19.3 ± 3 | >19.3 | 16.1 ± 1.0 | A |
| PIP | NZ | 19.3 ± 3 | >19.3 | 14.0 ± 2.0 | A | ||
| TCC | NZ | 19.3 ± 3 | >19.3 | 27.5 ± 1.3 | S | ||
| cephalosporines | CTX | NZ | 19.3 ± 3 | >19.3 | 17.0 ± 2.0 | A | |
| CAZ | NZ | 19.3 ± 3 | >19.3 | 22.7 ± 1.5 | S | ||
| FEP | NZ | 19.3 ± 3 | >19.3 | 24.5 ± 0.9 | S | ||
| carbapenems | IMP | NZ | 19.3 ± 3 | >19.3 | 24.8 ± 0.3 | S | |
| aminoglycosides | AK | 6.0 ± 0.0 | 19.3 ± 3 | >25.3 | 34.0 ± 1.0 | S | |
| TOB | 9.0 ± 0.0 | 19.3 ± 3 | >28.3 | 29.0 ± 3.0 | S | ||
| fluoroquinolones | CIP | 8.0 ± 0.0 | 19.3 ± 3 | >27.3 | 24.7 ± 0.6 | A | |
| NA | NZ | 19.3 ± 3 | >19.3 | 18.5 ± 1.3 | A | ||
| monobactames | AT | 4.0 ± 0.0 | 19.3 ± 3 | >23.3 | 16.8 ± 1.8 | A | |
a The inhibition zone non includes the diameter of the disc, and values are given as the mean ± standard deviation; b A, antagonism; S, synergism; NZ, no inhibition zone; OX, oxacillin; CX, cefoxitin; Van, vancomycin; TIC, ticarcillin; PIP, piperacillin; TCC, ticarcillin–clavulanic acid; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; IMP, imipenem; AK, amikacin; TOB, tobramicin; CIP, ciprofloxacin; NA, nalidixic acid; AT, aztreonam.
IZDs a (mm) of A. herba alba essential oil and antibiotics, alone and in combination, against MRSA S19 and IRABS3310 bacteria.
| Groups | Antibiotics | Inhibition Zone a with the Antibiotics | Inhibition Zone a with the Essential Oil | Sum of the Inhibitions Zone a with the Antibiotics and the Essential Oil | Inhibition Zone a with the Antibiotics and the Essential Oil in Association | Effects b | |
|---|---|---|---|---|---|---|---|
|
| penicillin | OX | 13.0 ± 0.0 | 07.5 ± 0.0 | >20.5 | 20.8 ± 0.6 | I |
| cephalosporines | CX | 13.5 ± 0.0 | 07.5 ± 0.0 | >21.0 | 29.0 ± 0.0 | S | |
| glycopeptids | VAN | 11.5 ± 0.0 | 07.5 ± 0.0 | >19.0 | 17.7 ± 0.3 | A | |
|
| penicillin | TIC |
| 9.3 ± 0.6 | >09.3 | 09.6 ± 2.1 | I |
| PIP |
| 9.3 ± 0.6 | >09.3 | 06.6 ± 1.3 | A | ||
| TCC |
| 9.3 ± 0.6 | >09.3 | 10.5 ± 0.5 | S | ||
| cephalosporines | CTX |
| 9.3 ± 0.6 | >09.3 | 13.3 ± 2.6 | S | |
| CAZ |
| 9.3 ± 0.6 | >09.3 | 09.6 ± 2.1 | I | ||
| FEP |
| 9.3 ± 0.6 | >09.3 | 08.8 ± 1.0 | A | ||
| carbapenems | IMP |
| 9.3 ± 0.6 | >09.3 | 10.8 ± 1.6 | S | |
| aminoglycosides | AK | 6.0 ± 0.0 | 9.3 ± 0.6 | >15.3 | 13.0 ± 2.6 | A | |
| TOB | 9.0 ± 0.0 | 9.3 ± 0.6 | >18.3 | 17.0 ± 2.0 | A | ||
| fluoroquinolones | CIP | 8.0 ± 0.0 | 9.3 ± 0.6 | >17.3 | 15.3 ± 1.0 | A | |
| NA | NZ | 9.3 ± 0.6 | >09.3 | 10.3 ± 1.5 | S | ||
| monobactames | AT | 4.0 ± 0.0 | 9.3 ± 0.6 | >13.3 | 09.5 ± 3.3 | A | |
a The inhibition zone non includes the diameter of the disk, and values are given as the mean ± standard deviation; b A, antagonism; S, synergism; NZ, no inhibition zone; OX, oxacillin; CX, cefoxitin; VAN, vancomycin; TIC, ticarcillin; PIP, piperacillin; TCC, ticarcillin–clavulanic acid; CTX, cefotaxime; CAZ, ceftazidime; FEP, cefepime; IMP, imipenem; AK, amikacin; TOB, tobramicin; CIP, ciprofloxacin; NA, nalidixic acid; AT, aztreonam.